title: [Intensity modulated radiation therapy for patients with gynecological malignancies after hysterectomy and chemotherapy/radiotherapy].
abstract: OBJECTIVE
  To investigate the value of intensity modulated radiation therapy (IMRT) for patient with gynecological malignancies after treatment of hysterectomy and chemotherapy/radiotherapy.
  
  
  METHODS
  All 32 patients with cervical or endometrial cancer after hysterectomy received full course IMRT after 1 to 3 cycles of chemotherapy (Karnofsky performance status(KPS) > or =70). Seventeen of these patients underwent postoperative preventive irradiation and the other 15 patients were pelvic wall recurrence and/or retroperitoneal lymph node metastasis, though postoperative radiotherapy and/or chemotherapy had been given after operation.
  
  
  RESULTS
  The median dose delivered to the PTV was 56.8 Gy for preventive irradiation, and 60.6 Gy for pelvic wall recurrence or retroperioneal lymph node metastasis irradiation. It was required that 90% of iso-dose curve could covere more than 99% of GTV. However, The mean dose irradiated to small intestine, bladder, rectum, kidney and spinal cord was 21.3 Gy, 37.8 Gy, 35.3 Gy, 8.5 Gy, 22.1 Gy, respectively. Fourteen patients presented grade I (11 patients) or II (3 patients) digestive tract side-effects, Five patients developed grade I or II bone marrow depression. Twelve patients had grade I skin reaction. The overall 1-year survival rate was 100%. The 2- and 3- year survival rate for preventive irradiation were both 100%, but which was 5/7 and 3/6 for the patients with pelvic wall recurrence or retroperioneal lymph node metastasis.
  
  
  CONCLUSIONS
  Intensity modulated radiation therapy can provide a better dose distribution than traditional radiotherapy for both prevention and pelvic wall recurrence or retroperioneal lymph node metastasis. The toxicity is tolerable. The adjacent organs at risk can well be protected.
authors.affiliation: Department of Gynecological Oncology, Shandong Cancer Hospital, Jinan, China.
authors.forename: Zhen-yun
authors.initials: ZY
authors.lastname: Chen
authors.forename: Yue-bing
authors.initials: YB
authors.lastname: Ma
authors.forename: Xiu-gui
authors.initials: XG
authors.lastname: Sheng
authors.forename: Xiao-ling
authors.initials: XL
authors.lastname: Zhang
authors.forename: Li
authors.initials: L
authors.lastname: Xue
authors.forename: Qu-qing
authors.initials: QQ
authors.lastname: Song
authors.forename: Nai-fu
authors.initials: NF
authors.lastname: Liu
authors.forename: Hua-qin
authors.initials: HQ
authors.lastname: Miao
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D003967:Diarrhea / Q000209:etiology; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects / Q000379:methods*; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery